Amicus Therapeutics Inc
A biotechnology company that makes treatments for rare genetic diseases. Its best-known product, Galafold, is an oral pill that helps people with Fabry disease, a condition that damages organs; it also developed a therapy for Pompe disease. Founded in 2002, Amicus traces its start to John Crowley, a father who entered biotech to find a treatment after two of his children were diagnosed with Pompe disease — a story that inspired the 2010 film "Extraordinary Measures." Its name, Amicus, is Latin for "friend," a nod to its collaborative work with patients.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| THE GOLDMAN SACHS GROUP, INC. | 13G/APassive | 0% | 0 | Aug 12, 2026 |
| GOLDMAN SACHS & CO. LLC | 13G/APassive | 0% | 0 | Aug 12, 2026 |
| Barclays PLC | 13GPassive | 5.65% | 17.76M | May 14, 2026 |
| UBS Group AG | 13GPassive | 5.5% | 17.14M | May 7, 2026 |
| Glazer Capital, LLC | 13GPassive | 0% | 0 | May 1, 2026 |
| Paul J. Glazer | 13GPassive | 0% | 0 | May 1, 2026 |
| Vanguard Capital Management | 13GPassive | 5.2% | 16.35M | Apr 29, 2026 |
| The Vanguard Group | 13G/APassive | 0% | 0 | Mar 26, 2026 |
| Wellington Management Group LLP | 13G/APassive | 0.4% | 1.37M | Feb 10, 2026 |
| Wellington Group Holdings LLP | 13G/APassive | 0.4% | 1.37M | Feb 10, 2026 |